Cover Image

Letter: Prospective Individualised Validation of the GES in Predicting Hepatocellular Carcinoma—A ‘Precision Medicine’ Study

Fuente: Wiley Open Access

Saved in:

Bibliographic Details
Main Author:	Ahmed Helmy
Format:	Artículo Open Access
Published:	Wiley 2025
Subjects:	Alimentary Pharmacology & Therapeutics
Online Access:	Acceder al recurso
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Letter: Prospective Individualised Validation of the GES in Predicting Hepatocellular Carcinoma—A ‘Precision Medicine’ Study: Authors' Reply
by: Gamal Shiha, et al.
Published: (2025)

Letter: Tumour Burden Score for Predicting Extrahepatic Metastasis in Hepatocellular Carcinoma After Curative Resection. Authors' Reply
by: Elisa Pinto, et al.
Published: (2026)

Letter: Methodological Considerations in Interpreting Polygenic Risk Scores for Hepatocellular Carcinoma After SVR
by: Zhejin Shi, et al.
Published: (2026)

Letter: Beyond Association—Operationalising PRS ‐5 for Hepatocellular Carcinoma Surveillance. Authors' Reply
by: Yu‐Sheng Lin, et al.
Published: (2026)

Risk Prediction of Early‐Onset Hepatocellular Carcinoma: Derivation and Validation in a Nationwide Young Adult Cohort
by: Seogsong Jeong, et al.
Published: (2026)

Letter on ‘Association Between Viral Replication Activity and Postoperative Recurrence of HBV‐Related Hepatocellular Carcinoma’
by: Dong Hyun Kim, et al.
Published: (2025)

Letter: Association Between Viral Replication Activity and Postoperative Recurrence of HBV‐Related Hepatocellular Carcinoma
by: Sifu Yang
Published: (2025)

PNPLA3 Genotype and Clinical Factors Impact Hepatocellular Carcinoma Risk: Findings From a Prospective Cohort Study
by: Daniel Q. Huang, et al.
Published: (2026)

Letter: Methodological Considerations in Interpreting Polygenic Risk Scores for Hepatocellular Carcinoma After SVR . Authors' Reply
by: Yu‐Sheng Lin, et al.
Published: (2026)

Letter on “Association Between Viral Replication Activity and Postoperative Recurrence of HBV‐Related Hepatocellular Carcinoma”–Authors' Reply
by: Subin Heo, et al.
Published: (2025)

Letter: Association Between Viral Replication Activity and Postoperative Recurrence of HBV‐Related Hepatocellular Carcinoma—Authors' Reply
by: Jiwon Yang, et al.
Published: (2025)

Letter: Does Serum HBV RNA Add Incremental Value for Hepatocellular Carcinoma Risk Stratification Beyond Established Predictors?
by: Yuanyan Sun, et al.
Published: (2026)

Research Communication: Serum Metabolomic Signatures Predict Tumour Recurrence After Resection or Ablation in Patients With Early‐Stage Hepatocellular Carcinoma
by: Ashwini Arvind, et al.
Published: (2025)

Prevalence of Low FIB‐4 in MASLD‐Related Hepatocellular Carcinoma: A Multicentre Study
by: Darren Jun Hao Tan, et al.
Published: (2024)

Letter: ‘Impact of HCV Eradication on Recurrence Pattern and Long‐Term Outcomes in Patients With HCV‐Related Hepatocellular Carcinoma Undergoing Radiofrequency Ablation’
by: You‐Jian Xu, et al.
Published: (2024)

Letter: Enhancing HCC Surveillance– GES Score Represents an Innovative Simple Effective Tool for Risk Stratification, Patient Safety and Reduced Anxiety
by: Ibrahima Gueye
Published: (2025)

Letter: Impact of HCV Eradication on Recurrence Pattern and Long‐Term Outcomes in Patients With HCV‐Related Hepatocellular Carcinoma Undergoing Radiofrequency Ablation. Authors' Reply
by: Kuo‐Cheng Wu, et al.
Published: (2024)

Letter: Enhancing HCC Surveillance: GES Score Represents an Innovative Simple Effective Tool for Risk Stratification, Patient Safety and Reduced Anxiety—Authors' Reply
by: Gamal Shiha, et al.
Published: (2025)

Clinical Course and Prognosis of Long‐Term Survivors of Hepatocellular Carcinoma
by: Soon Sun Kim, et al.
Published: (2025)

Letter: A Prospective Study on the Prevalence of MASLD in Patients With Type 2 Diabetes and Hyperferritinaemia
by: Xiaojuan Liu, et al.
Published: (2025)

Editorial: Direct‐Acting Agents and Risk of Hepatocellular Carcinoma—The End of Controversy
by: Vincent Haghnejad, et al.
Published: (2025)

Risk of Variceal Bleeding in Patients Receiving Atezolizumab–Bevacizumab Treatment for Hepatocellular Carcinoma
by: Kanghee Park, et al.
Published: (2025)

Editorial: Genotyping for Hepatocellular Carcinoma Risk Stratification in the General Population. Authors' Reply
by: Daniel Q. Huang, et al.
Published: (2026)

Editorial: Predicting Hepatocellular Carcinoma Development in Chronic Hepatitis B Patients With Metabolic Dysfunction—Do Existing Scores Clear the Bar?
by: Danny Con
Published: (2025)

Very Early‐Stage Detection Is Associated With Improved Survival in Patients With Unifocal Hepatocellular Carcinoma
by: Thomas Hunold, et al.
Published: (2025)

Camrelizumab and Apatinib With or Without Transarterial Chemoembolisation as First‐Line Treatment for Advanced Hepatocellular Carcinoma
by: Rong Ding, et al.
Published: (2026)

Review Article: Individualised Management of Reflux‐Like Symptoms—Strategies Beyond Acid Suppression
by: Peter J. Kahrilas, et al.
Published: (2025)

Editorial: Predicting Hepatocellular Carcinoma Development in Chronic Hepatitis B Patients With Metabolic Dysfunction—Do Existing Scores Clear the Bar? Authors' Reply
by: Lesley A. Patmore, et al.
Published: (2025)

Factors Associated With Underutilization of Antiviral Therapy in Preventing Hepatitis B Virus‐Related Hepatocellular Carcinoma
by: Jia‐Ling Wu, et al.
Published: (2025)

Editorial: Immune Checkpoint Inhibitors in Hepatocellular Carcinoma Prior to Liver Transplantation—Current Evidence and Future Directions
by: Mohammad Saeid Rezaee‐Zavareh, et al.
Published: (2026)

Editorial: Understanding the Role of the Alpha‐1 Pi* MZ Genotype in the Development of Hepatocellular Carcinoma for Patients With ACLD
by: Kaitlyn Carlson, et al.
Published: (2026)

Clinical Trial: Early Nivolumab Addition to Regorafenib in Patients With Hepatocellular Carcinoma in Second‐Line (The GOING Trial)
by: Marco Sanduzzi‐Zamparelli, et al.
Published: (2026)

Editorial: Predicting Hepatocellular Cancer in Clinical Practice. Authors' Reply
by: Shuaibing Ying, et al.
Published: (2026)

Letter on ‘Head‐to‐Head Comparison Between Phosphatidylethanol Versus Indirect Alcohol Biomarkers for Diagnosis of MetALD Versus MASLD: A Prospective Study’
by: Muhammad Abubakr, et al.
Published: (2025)

Editorial: Variceal Bleeding in Patients Receiving Atezolizumab–Bevacizumab for Hepatocellular Carcinoma—Don't Ignore the Risk Factors! Authors' Reply
by: Jonggi Choi
Published: (2025)

Editorial: Flipping the Script—Higher Risk of Hepatocellular Carcinoma With Tenofovir Compared to Entecavir in a French Population‐Based Cohort
by: Ariel Lee, et al.
Published: (2025)

Therapeutic Sequences of Systemic Therapy After Atezolizumab Plus Bevacizumab for Hepatocellular Carcinoma: Real‐World Analysis of the IMMUreal Cohort
by: Najib Ben Khaled, et al.
Published: (2025)

Editorial: Immune Checkpoint Inhibitors in Hepatocellular Carcinoma Prior to Liver Transplantation—Current Evidence and Future Directions. Authors' reply
by: L. Aceituno, et al.
Published: (2026)

Letter: Fecal VOCs in Lynch Syndrome: Sample Stability, Specificity and Statistical Validation
by: Xidi Yang, et al.
Published: (2026)

Letter: From Safety to Precision—Optimising the Use of GLP‐1 Receptor Agonists in Gastroenterology
by: Joëlle St‐Pierre, et al.
Published: (2026)